Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 6:44 PM ET


Company Overview of Human Genome Sciences Inc.

Company Overview

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The company’s mid- and early-stage pipeline products comprise Mapatumumab, a human monoclonal antibody for the treatment of advanced hepatocellular cancer; HGS1036, a biologic for multiple cancers; HGS1029, an IAP inhibitor that is in Phase 1 development to treat patients with solid and lymphoid tumors; and HGS1025, a human monoclonal antibody to the CCR5 receptor that would have entered Phase 1b development in ulcerative colitis. It also holds financial rights to certain products in the Gla...

14200 Shady Grove Road

Rockville, MD 20850-7464

United States

Founded in 1992

1,100 Employees





Key Executives for Human Genome Sciences Inc.

Chief Executive, President and Director
Age: 54
Senior Vice President of Operations
Age: 53
Executive Vice President, Secretary and General Counsel
Age: 63
Executive Vice President of Research & Development
Age: 65
Vice President and Chief Information Officer
Compensation as of Fiscal Year 2015.

Human Genome Sciences Inc. Key Developments

GSK Reportedly To Acquire Human Genome

GlaxoSmithKline plc (LSE:GSK) is reportedly expected to announce an agreement to acquire Human Genome Sciences Inc. for about $2.8 billion. GlaxoSmithKline is expected to pay around $14 per share.

Similar Private Companies By Industry

Company Name Region
Dynamis Therapeutics, Inc. United States
Gel Med Sciences, Inc. United States
ZymoChem, Inc. United States
Resolvyx Pharmaceuticals, Inc. United States
Osprey Pharmaceuticals USA, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Human Genome Sciences Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at